MedPath

Controlled Crossover Study of AIONX Antimicrobial Surface for the Prevention of Healthcare-associated Infections

Phase 2
Conditions
Healthcare Associated Infection
Interventions
Device: Antimicrobial Surface
Registration Number
NCT03189043
Lead Sponsor
Aionx, Inc.
Brief Summary

This is a controlled open label efficacy study of Aionx antimicrobial surface for the prevention of healthcare-associated infections.

Detailed Description

The study is an open label controlled efficacy trial of Aionx patented antimicrobial surface for the prevention of healthcare-associated infections (HAIs). It will take place at Penn State Hershey. Half of the single occupancy rooms of the 5th and 7th floor will be assigned to contain the antimicrobial surface at five locations: bed rails, overbed table, door handles, counter, and arm rests of bedside chair. The remaining rooms will serve as controls. Data on HAIs will be gathered for all the patients admitted to the rooms during the duration of the study. After 45 days the rooms will be flipped so that test rooms become controls and control rooms become test rooms. The duration of the study will be for a minimum of 90 days.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
10000
Inclusion Criteria
  • Admission to a single occupancy room in a participating floor at Hershey Medical Center
Exclusion Criteria
  • Refusal to participate in the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
TestAntimicrobial SurfaceUse of antimicrobial surface
Primary Outcome Measures
NameTimeMethod
Healthcare-Associated Infections90 days

Healthcare-Associated Infections

Secondary Outcome Measures
NameTimeMethod
30-day Readmission for infection90 days
© Copyright 2025. All Rights Reserved by MedPath